Answers are grounded in this paper and cite their sources.
Background. PIK3CA mutations are detected in up to 40 % of luminal breast cancer (BC) cases and are associated with hormone resistance. However, the prognostic significance of these mutations and their impact on the course of early BC remain debated. Aim. To analyze clinical and morphological factors determining prognosis of PIK3CA-associated early breast cancer. Materials and methods. A retrospective single-center cohort study was conducted. Among 635 patients who underwent molecular genetic testing, PIK3CA mutation was found in 230 (36.2 %). The final analysis included 133 patients with luminal HER2– early BC who received radical surgical treatment. Clinical and morphological characteristics, median recurrence-free survival (mRFS), and prognostic factors were assessed. Results. The common hotspot mutations H1047, E542, and E545 were detected in 88.7 % of patients and were associated with a better prognosis compared to rare mutations (mRFS 54 months vs 28 months; hazard ratio 0.57; log-rank p = 0.38). At initial diagnosis, tumor stage was I in 12.8 %, II in 50.4 %, and III in 36.8 % of cases. Overall mRFS in the entire radically treated cohort was 62 months (95 % confidence interval 48–76). Univariate analysis showed no statistically significant differences in mRFS for different immunohistochemical subtypes (luminal A vs luminal B; p = 0.62), administration of adjuvant radiotherapy (p = 0.39), or type of surgery (breast-conserving surgery vs mastectomy; p = 0.47). However, the use of neoadjuvant or adjuvant chemotherapy compared with no chemotherapy (62 months vs 31 months; hazard ratio 0.26; log-rank p = 0.01) and the choice of tamoxifen over aromatase inhibitors as adjuvant endocrine therapy (67 months vs 21 months; hazard ratio 0.17; log-rank p 0.0001) demonstrated significant effects. Conclusion. Early breast cancer with PIK3CA mutations is highly heterogeneous in clinical course and treatment sensitivity; development of hormone resistance is a distinct, clinically defined phenomenon (based on recurrence timing during endocrine therapy) and is not equivalent to mutation itself.
No takes yet. Share an insight, caveat, or question.
Gluzman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: